Lenalidomide (Revlimid) significantly reduced the risk for smoldering multiple myeloma to progress to cancer among patients with moderate to high risk, according to findings from the phase II/III E3A06 trial to be presented at the 2019 ASCO Annual Meeting. “It is pretty clear that we need to differentiate treatment of myeloma versus prevention of smoldering to developing myeloma,” Sagar...Continue Reading